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 Electrically functional neural interfaces are becoming a powerful toolkit for clinical 11 
interventions requiring stimulation and/or recording of the electrical activity of the nervous 12 
system. Active implantable devices offer a promising approach for the treatment of various 13 
diseases affecting the central nervous or peripheral nervous systems by electrically 14 
stimulating different neuronal structures 1. Deep brain stimulation (DBS), based on the 15 
electrical stimulation of deep structures within the brain, is clinically used for the symptomatic  16 
treatment of motor-related disorders, such as Parkinson’s disease, dystonia and tremor, and 17 
is under clinical development for other drug-resistant neurological disorders, such as 18 
depression, obsessive-compulsive disorder and others 2. Even more widely used clinically, 19 
cochlear implants  aim at converting external sound waves recorded by a microphone and 20 
transformed into electrical impulses sent along an electrode array that stimulates the 21 
cochlea’s hearing nerve3. Conceptually similar to cochlear implants, eye prostheses (retinal 22 
implants) are intended to partially restore vision in blind patients suffering from retinal 23 
diseases leading to the loss of photoreceptors4. Electrical stimulation of the central (CNS) 24 
and peripheral nervous systems (PNS) can also be achieved by implanted neuroprosthetic 25 
devices at the spinal cord or peripheral nerves and muscles to restore sensory and motor 26 
function in a novel and promising field of therapeutic interventions termed ‘bioelectronics’5.  27 
 Neural interfaces whose main functionality is to record electrical activity of the brain 28 
aim to address clinical needs different to those discussed above. Recording electrodes in the 29 
context of basic electrophysiology research have been central to our understanding of action 30 
potentials produced by individual neurons, as well as to provide novel insights into cell-to-cell 31 
coupling phenomena that eventually lead to the genesis of neural networks6.  32 
Electrophysiological recordings of brain activity can be performed by positioning electrode 33 





































































and within the cortex. Non-invasive electrodes located on the scalp or close to the dura 1 
mater allow recording of the global activity of different areas in the brain, hence provide 2 
useful functional information. However, intracranial electrodes are able to record electrical 3 
signals with better spatial and time resolution and are the choice for several clinical 4 
applications. For example, cortical neural interfaces are employed in the acute clinical 5 
setting for diagnostic purposes and/or for pre-interventional brain mapping related to surgery 6 
for neurological disorders. More specifically,  intracranial neurophysiology is routinely applied 7 
in the surgical treatment of epilepsy, brain tumours, pain or even psychiatric conditions7.  8 
 Taking the concept of brain activity recording one step further, brain-machine 9 
interfaces (BMI) aim at recording the activity of a single or group of neurons using an 10 
electrode array, subsequently processing and digitizing the collected signals that are sent as 11 
commands to external devices.8 Clinically, current effort is directed towards the development 12 
of motor BMIs for control of robotic upper limbs9. In addition to restoration of motor 13 
functionality, cortical BMIs are also employed to enhance communication with patients with 14 
severe neurological disorders (e.g. spinal cord injury, amyotrophic lateral sclerosis) using a 15 
typing interface 10 or, eventually, a speech prosthesis 11.   16 
 Figure 1 describes the different classes of implantable devices used as neural 17 
interfaces for clinical applications as well as novel areas of applications that have not 18 
reached broad clinical implantation yet. All these devices have reached different stages of 19 
clinical development, but they are all based on the same concept of direct interaction with 20 
neural elements in different tissues, connected through wired means to a power source and 21 
digital processors. It is important to note that all currently used neural interface devices are 22 
designed to perform a single function, either record activity or electrically stimulate tissue. As 23 
can be seen from Figure 1, current neural interfaces used in clinical applications are rather 24 
elementary designs, mostly based on arrays of few (tens) and large (mm size) metal 25 
electrodes. That is in sharp contrast to the potential offered by microelectronic-based 26 
designs that include very high integration density as well as on-site signal processing and 27 
transmission.   28 
 29 
Materials for neural implants 30 
 Due to the complexity of the human nervous system and the intricacy of the 31 
anatomical sites where implantation is required, the success of novel clinical implant 32 
technologies requires the use of advanced materials and flexible electronic technologies. 33 




































































allow for a facile surgical procedure, and provide efficient and consistent activity for the 1 
duration of its functional lifetime. This can range from several hours for acute experiments 2 
(e.g. cortical recording for brain mapping of epileptic lesions) to several years for chronic 3 
applications (e.g. cochlear implants or DBS electrodes). Some key requirements to achieve 4 
this are: a) biocompatibility with minimal inflammatory (local or systemic) responses from the 5 
neural tissue; b) suitable charge injection capabilities for stimulation applications; c) 6 
adequate signal-to-noise ratio in case of neural recording; and d) mechanical compliance 7 
with neural tissues. The technological challenges required to achieve sufficient levels of 8 
efficacy are summed up in Box 1. 9 
 Tremendous effort has been expended over the last decade in the development of 10 
novel materials into devices that combine high double layer capacitance (associated to the 11 
electrical double layer induced at the electrochemical interface between a conductive 12 
electrode and an electrolyte) for both stimulation and recording, biocompatibility toward 13 
neural tissue by increased “softness” and flexibility of the substrates. Table 1 and Table 2 list 14 
characteristics of some of the materials currently used in neural interfaces. Despite the 15 
reported performance of those materials and the substrates that have integrated them, their 16 
chemical and mechanical stability are still unresolved, posing concerns with regards to their 17 
clinical translation. For instance, IrOx is subject to corrosion, CNTs might detach from the 18 
electrode substrate and PEDOT substrates can degrade over time in aqueous solutions12. In 19 
the meantime, flexible implantable scaffolds are being developed to closely conform the 20 
cerebral anatomy and to facilitate the insertion of the implant. Radically new implant shapes 21 
and structures based on three-dimensional nanoelectronic probes13 or syringe-injectable 22 
mesh-like metal structures14, as well as on nanomembranes of crystalline silicon15 have 23 
been recently proposed. 24 
 Despite recent advancements, current neural interface materials have not been 25 
proved yet to meet all the challenges discussed above, in many cases due to stability issues 26 
but also to technology limitations related to these materials. Efforts to develop and integrate 27 
new materials that can offer as many options as possible for the design of neural interface 28 
devices with multiple capabilities and functionalities are essential for the development of 29 
next-generation flexible neural implants. 30 
 31 
Graphene materials for next-generation neural interfaces 32 
 Because of their electrical and electrochemical performance and their suitability for  33 
integration into flexible devices, graphene-based materials constitute a versatile platform that 34 




































































Different studies have assessed the biocompatibility of graphene with neural cells and its 1 
ability to functionally interface with neuronal tissue. Cultures of neural cells on 2D graphene 2 
substrates have been found to exhibit enhanced adhesion, good viability as well as improved 3 
neurite sprouting and outgrowth 16, 17, 18. The issue of biodegradability of graphene and other 4 
2D materials is also important, but much more challenging to determine in a generalised 5 
manner. A few studies have already reported the biodegradation of graphene nanomaterials 6 
using enzymes, such as horseradish peroxidase 19, 20, 21. In the design of implantable 7 
devices, material degradability will need to be ensured in the event of exfoliation or tear. 8 
However, the substrate will need to maintain structural stability post-implantation, especially 9 
in cases of long-term implants. Longitudinal assessment studies to address the 10 
biocompatibility, biodegradation and overall safety of the graphene-based neural devices is 11 
warranted and will be imperative. 12 
 The conductive properties of CVD graphene planar substrates have been used to 13 
electrically stimulate human neural stem cells and hence direct their differentiation towards a 14 
neuronal phenotype 22. Three-dimensional graphene-based scaffolds have also been 15 
explored to stimulate adult hippocampal neural stem cells, for instance showing preferred 16 
differentiation toward astrocytes and neurons23. GO porous hydrogels also allowed the 17 
differentiation of embryonic neural progenitor cells to both neuron and glial cells with 18 
reasonably high formation of dendrites, axons and synaptic connexions 24. It has become 19 
apparent that the capacity of graphene to interface with neuronal tissue effectively and 20 
functionally allows the fabrication of devices for electrical recording and stimulation. In 21 
combination with technologies for therapeutic molecule controlled release, the use of 22 
graphene-based neural interface implants could achieve optimum integration with the 23 
surrounding tissue while minimising the formation of the fibrotic capsule building around 24 
electrodes, as shown in Figure 2 and further elaborated in the sections that follow. 25 
Graphene-based materials for neural stimulation. Effective stimulation of neuronal tissue 26 
devoid of damage or adverse (e.g. neuroinflammatory) reaction is required for electrodes 27 
used in deep brain, cortical and intra-cortical, or spinal cord stimulation for motor BCIs, 28 
cochlear and retinal implants, as well as in peripheral nervous system applications. To elicit 29 
a functional response, electrical stimulation requires a minimum level of charge injection to 30 
depolarise the membrane of excitable cells in the vicinity of the stimulating electrode, which 31 
can typically vary between tens of µC/cm2 and several mC/cm2 depending on the tissue to 32 
be stimulated. The charge injection level provided by the electrode depends on the 33 
electrolytic double layer capacitance of the material and on its potential window in water. 34 
 Typical reported values for such interfacial capacitance of non-structured CVD grown 35 




































































for a 1V potential window in water), slightly lower than standard noble metal electrodes like 1 
Pt and Au and well below the tens of mF/cm2 offered by alternative novel materials proposed 2 
for neural stimulation, such as PEDOT-CNT or IrOx 25. However, recent studies have shown 3 
that when used in porous thin-films processed from flakes or introduced in polymer 4 
composites26 27, graphene-based materials can exhibit  dramatically improved performance 5 
for neural stimulation. For instance, porous graphene oxide electrodes reduced by laser 6 
treatment28,29 and by the Langmuir-Blodgett method30 have been reported to be able to 7 
stimulate neural tissues with outstanding charge injection values between 1 and 3 mC/cm2. 8 
Furthermore, new promising materials are expected to emerge from the very active research 9 
field of the supercapacitors, in which graphene-based materials exhibiting very large active 10 
surface area are being developed achieving very high double layer capacitance.  For 11 
instance, free standing porous graphene grown by CVD has been reported to exhibit double 12 
layer capacitance values exceeding tens of mF/cm2, 31, 32, 33. The free standing graphene 13 
films are obtained by using a porous sacrificial scaffold or by tuning the growth parameters in 14 
order to obtain vertical growth of graphene walls.  More interesting, reduced graphene oxide 15 
foams that can be obtained by a variety of procedures show unparalleled values of 16 
volumetric charges, which indicates very promising charge injections 34,35,36. These materials, 17 
however, have not yet been integrated into microelectrodes and thus have to be tested for 18 
neural applications. Considering the capacitance and charge injection values given above, 19 
structured or 3D films of graphene-based materials, as well as composite films including 20 
graphene, show significant potential for stimulation applications. 21 
Graphene for electrical neural recording. Monitoring electrical brain activity brain requires 22 
recording signals of individual neurons (down to few tens of µV) and of assemblies of 23 
neurons (inducing potentials of few hundreds of µV or even mV) over large areas that can 24 
reach up to few tens of cm2. In order to achieve this, recoding technologies offering both 25 
high spatial resolution and temporal resolution need to be developed. However, when the 26 
dimensions of a recording electrode reduce to a few tens of microns, its impedance can 27 
become so high that the electrode’s intrinsic noise levels can be well above the signal levels 28 
of action potentials. In this case, electrode materials with a high double layer capacitance 29 
(i.e. low interfacial impedance) should be used. 30 
 Graphene exhibits electrochemical capabilities for neural recording similar to 31 
platinum or gold, which have been for long the standard electrode materials for neural 32 
recording. Although recent studies have demonstrated the successful recording of local field 33 
potentials from the rat cortex using graphene37, 38, the relatively low double layer capacitance 34 
of single layer or few layer graphene results in a high impedance, and thus large thermal 35 




































































(diameter below 20µm). Similarly to the case of neural stimulation, the performance of 1 
graphene-based materials for recording applications can greatly improve by using structured 2 
or 3D films that increase the specific surface area of the electrode. This has been recently 3 
shown28, 29  by recording in vivo brain activity using porous graphene-related materials with a 4 
good signal-to-noise ratio. 5 
 In contrast to standard metals used in neural interfaces, graphene offers an unique 6 
advantage for recording applications: whereas metals only allow for designs based on the 7 
electrode configuration, graphene can be used to fabricate sensors based on a field-effect 8 
transistor (FET) configuration39. In this configuration, the recording mechanism is based on 9 
the modulation of the transistor current induced by the electrical activity in the vicinity of the 10 
transistor’s gate. An important benefit of the transistor recording configuration is its intrinsic 11 
signal amplification, which reduces the sensitivity to external noise. In addition, the transistor 12 
configuration allows the design of sensor arrays with a level of integration density beyond 13 
that offered by electrodes. Due to these advantages, FETs based on various materials 14 
(silicon40, organic semiconductors41, diamond42) have been explored to record neural 15 
activity. In the case of graphene, which is suitable for integration with flexible substrates, the 16 
exceptional mobility of charge carriers results in graphene FETs exhibiting a high 17 
transconductance, a figure of merit for the transistor amplifying capability43, that together 18 
with the low intrinsic noise of graphene FETs leads to recording capabilities with high signal-19 
to-noise ratio. It has been already demonstrated that arrays of flexible FETs based on CVD 20 
graphene with a transconductance over 1mS/V can detect action potentials of electrically 21 
active cells in vitro44 as well as the brain activity in acute in vivo experiments45. 22 
Graphene for controlled drug delivery at the neural interface. Graphene and its 23 
derivatives are actively being explored in the field of therapeutic agent transport as 24 
nanoplatforms able to carry compounds of biological activity to specific cell populations and 25 
intracellularly. π-π stacking between GO flakes and the aromatic rings present in various 26 
therapeutic compounds (e.g. doxorubicin, camptothecin, heparin) have been described. 27 
Other types of non-covalent complexation (e.g. with nucleic acids) is also of great interest in 28 
the context of gene therapy applications46. In combination with neural interface technologies, 29 
graphene flakes can be integrated as nanocarriers able to coat neural electrodes and be 30 
released for the in situ delivery of dopamine, microglial inhibitors (such as minocycline or 31 
resveratrol) and anti-inflammatory agents such as dexamethasone. There are already 32 
various reports describing conjugation and release of dexamethasone from graphene-based 33 
polymeric nanocomposites47 or graphene-coated metal alloys used as dental implants48. 34 
 Design of electroresponsive graphene-based hydrogels have also been proposed for 35 




































































sheets are incorporated into a hydrogel matrix to enhance mechanical, electrical and thermal 1 
properties. In much earlier work following a similar approach, dexamethasone was loaded 2 
onto poly(lactic-co-glycolic acid) nanoparticles that were subsequently embedded into 3 
alginate hydrogels used to coat gold and iridium oxide electrodes for local administration 4 
after implantation 50, 51. Overall, such strategies could be employed to engineer smart 5 
coatings for neural implants able to release biologically-active molecules, to improve surface 6 
softness, and enhance neural recruitment and the overall biocompatibility of the implant. 7 
Graphene for in situ biosensing. Beyond the detection of electrical activity in the CNS or 8 
PNS, many applications of neural interfaces would hugely benefit from the capability of 9 
sensing biomolecules relevant to neurology. In this way, it would be possible to 10 
simultaneously map the electrical activity, the biochemistry and metabolic activity of neural 11 
tissue. For instance, the detection of neurotransmitters and neuromodulators such as 12 
dopamine, serotonin, acetylcholine, choline, or glutamate, or reporter molecules such as 13 
H2O2 would allow a better understanding of neurological disorders and tissue response to 14 
treatment.  15 
 Due to its electronic properties and large surface to volume ratio, graphene has been 16 
extensively studied in the context of biosensing applications, and a broad variety of devices 17 
exhibiting high sensitivity, low noise, and low detection limits have been reported. Both 18 
enzyme and other graphene-based biosensors have been used for the detection of 19 
biologically-relevant molecules such as glucose, DNA, or cholesterol. More relevant to 20 
neural interfaces, enzyme-modified graphene FETs have been used to demonstrate the 21 
detection of acethylcholine, a neuromodulator in the CNS and PNS52. Functionalised 22 
graphene and graphene/polymer composites have also been used for the detection of 23 
dopamine, a catecholamine neurotransmitter acting in the CNS53. To enable optimal 24 
modulation to therapeutic activity and intervention, graphene-based biosensors could be 25 
integrated as part of closed-loop system able to adapt the stimulation or therapeutic 26 
molecule release according to the level of biosensing readings at the implantation site. The 27 
main challenge in most biosensing designs is tailoring specificity of the recognition event. 28 
This has to be achieved by a controlled chemical modification of graphene to enable the 29 
specific recognition of neurotransmitters, neuromodulators, or other biomarkers.  30 
 31 
Outlook: Towards Multifunctional Graphene-based Neural Implants 32 
 In order to fully exploit the potential of neural interfaces, the forthcoming generation 33 
of devices is expected to simultaneously offer multiple functionalities, including recording 34 




































































other neurologically-relevant biomolecules, as well as the capability for a controlled drug 1 
delivery. Given their versatility, which results from a remarkable combination of physico-2 
chemical, structural and electronic properties, graphene-based materials can provide options 3 
in several, if not all, of such desired device functionalities. 4 
 For instance, microtransistors based on CVD graphene can be at the heart of flexible 5 
arrays capable of recording over large areas of the brain with very high spatial resolution. To 6 
overcome the limitation introduced by the excessive footprint of the large number of 7 
connections associated with the high density recording devices, graphene FETs have the 8 
additional advantage of enabling facile multiplexing by using flexible technology based on 9 
emerging 2D semiconductors, such as MoS2. 10 
 With respect to neuro-stimulation, three dimensional or structured graphene films  11 
exhibiting high porosity (or surface-to-volume ratio), such as CVD foams or rGO porous 12 
films, offer charge injection capacitances similar or superior to those of competing materials. 13 
Furthermore, graphene-related materials (graphene nanoflakes) can be used in hybrid thin 14 
films as a doping material to increase the film conductivity and thus to enhance the charge 15 
injection of these films. Graphene can also contribute by providing biosensing functionality 16 
on neural interfaces based on the reported high sensitivity of detection of electrical and 17 
chemical changes.  18 
 Graphene and other 2D materials possess an array of properties (flexibility, electrical 19 
mobility, large surface area available for interaction with the neuronal components and 20 
amenable to surface modifications) that can enable enhanced functional capabilities for 21 
neural interfaces. The technological challenges are similar for the different competing types 22 
of materials used in the engineering of such devices. We believe that each material can offer 23 
a unique set of advantages and limitations that – depending on the specific indication 24 
developed – will ultimately determine efficacious function and eventually clinical adoption. 25 
 26 
___________________ 27 
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BOX 1. Technology Challenges in Neural Interface Design 2 
 Recording capabilities should allow:  3 
 4 
- detection of signals of individual neurons (down to few tens of µV) and of assemblies of 5 
neurons (inducing field potentials of few hundreds of µV); 6 
 7 
- over large areas (up to few tens of cm2); 8 
 9 
- with high spatial resolution (hundreds of µm2 of the active recording site). 10 
  11 
 Electrical stimulation requires:  12 
 13 
- a minimum level of charge injection capacity in order to elicit a response in the tissue to 14 
be stimulated. Typically, electrode materials should be able to provide of the order of 15 
hundreds of µC/cm2 to few mC/cm2, in pulses between 100 µs and 1 ms. Such large charge 16 
injection capacity should allow focal stimulation with electrodes of active areas down to 17 
hundreds of µm2. 18 
 19 
 To minimize foreign body reaction, electrical neural interfaces should exhibit:  20 
 21 
- excellent biocompatibility and mechanical compliance of the neural tissue surrounding 22 
the device. 23 
  24 
- long-term stability of the implanted devices can be significantly enhanced by improving 25 
the mechanical mismatch between the nervous tissues (Young’s modulus ranging between 26 
100Pa and 10kPa) and the implantable devices (100GPa for rigid electronics, 5GPa for thin 27 
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Figure 1. Clinically developed neural interfaces. Schematics of the actual devices are shown (not 5 




























































































Figure 2. Neural interface functionalities enabled by incorporation of graphene material. By 9 
utilising the inherent properties that graphene materials offer, such as large surface area, flexibility, 10 
versatility for chemical  functionalisation and excellent performance of electronic devices, a variety of 11 
functionalities like recording, stimulation, biosensing and drug delivery at the neural interface could be 12 
engineered in various combinations. 13 
 14 




































































Table1: Characteristics of materials (including graphene) used as electrodes in neural 1 
interfaces. The values noted are as published in the respective reports.  2 
 3 













Metal-based PtIr 4500 8 0.13 90 25 
  Porous TiN 2830  5 0.7 55 54 
  IrOx 4500 0.2     25 
    177 29 1 113 55 
  Gold 155 0.4   1500 56 
  Pt grass 1256   0.3 100 57 
PEDOT-based PEDOT:PSS 4500 123 2.9 6 25 





314 10 3 171 58 
  CNTs 50000   1,6 2 59 
Graphene-
based 
SLG 2500 0.7   3000 38 
  Doped-SLG 2500 1.9   600 38 
  rGO foam 625000   3.1 0.5 29 
    120000 62   1 29 
PtIr: Platinum Irdium; TiN: Titanium Nitride; IrOx: Iridium Oxide; PEDOT: poly(3,4-ethylenedioxythiophene);  4 
PSS: polystyrenesulfonate; CNT: Carbon Nanotubes; SLG: Single Layer Graphene; rGO: reduced Graphene Oxide. 5 





































































Table 2: Noise performance of graphene and other materials used in neural interfaces.  2 
 3 
 Area(μm2) Type μVrms μVrms.μm2 Ref 
      
Porous 
Platinum 
113 electrode 2 226 60 
Porous 
Diamond 
314 electrode 3 942 58 
TiN 706 electrode 7-10 5000-7000 61 
Iridium 703 electrode 10 7030 62 
PEDOT:PSS 100 electrode 8 800 63 
Doped-SLG 2500 electrode 31 77500 38 
Gold 2500 electrode 165 412500 38 
SLG 200 transistor 7 1400 64 
TiN: Titanium Nitride; PEDOT: poly(3,4-ethylenedioxythiophene); PSS: polystyrenesulfonate; SLG: Single Layer Graphene. 4 
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